Company Filing History:
6 out of 2,894 
5 out of 1,999 
Years Active: 2002-2019
Title: **Innovations and Contributions of Inventor Hua Shi**
Introduction
Hua Shi, an accomplished inventor based in Ithaca, NY, has made significant contributions to the field of molecular biology. With a total of eight patents to his name, his work primarily focuses on nucleic acid aptamers and their applications in targeting estrogen receptors and complement proteins.
Latest Patents
Hua Shi's recent patent innovations include:
1. **Aptamer modulators of estrogen receptors** - This invention involves a nucleic acid aptamer molecule that is designed to bind specifically to an estrogen receptor. The patent describes the molecular complexes formed with the estrogen receptor and explores the use of these aptamers to inhibit estrogen receptor activity in cells, offering potential treatments for estrogen receptor-positive cancers.
2. **Aptamer modulators of complement protein C3 and biologically active proteolytic products thereof** - This patent focuses on nucleic acid aptamers that identify and bind to complement protein C3 and its active proteolytic products. The invention highlights preferred bifunctional aptamer constructs that can target both C3b or iC3b, along with another protein, providing innovative methods for manipulating the opsonization process.
Career Highlights
Hua Shi has contributed his expertise to several prominent institutions, including the State University of New York and the Cornell Research Foundation Inc. His work has gained recognition for its potential impact on cancer treatment and immune response modulation.
Collaborations
Throughout his career, Hua Shi has collaborated with distinguished colleagues such as John T. Lis and Li Niu. These collaborations have undoubtedly enriched his research and innovation portfolio.
Conclusion
Hua Shi's groundbreaking inventions and continuous research in the field of molecular biology signify his vital role as an inventor. With his dedication to advancing medical science, his innovations pave the way for new therapeutic strategies in fighting diseases closely associated with estrogen receptors and complement proteins.